Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

SciSparc Ltd. - Ordinary Shares (NQ: SPRC )

0.2477 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about SciSparc Ltd. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Pharma Company Gets FDA Green Light For Next Phase Trial For Tourette Syndrome
SciSparc secures FDA approval for Phase IIb clinical trial of SCI-110, targeting unmet needs in Tourette Syndrome, Global trial begins soon. 
Via Benzinga
Exposures Product Safety
SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment
From SciSparc Ltd
Via GlobeNewswire
SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX
From SciSparc Ltd
Via GlobeNewswire
SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment
From SciSparc Ltd
Via GlobeNewswire
Why Is SciSparc (SPRC) Stock Up 94% Today?
SciSparc stock is up on Thursday with heavy trading of SPRC shares after it provided an update on its merger with AutoMax. 
Via InvestorPlace
SciSparc Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome Treatment
From SciSparc Ltd
Via GlobeNewswire
Clearmind Medicine Files International Patent For Ibogaine Combination Therapy
Clearmind Medicine filed an international patent for a treatment that aims to enhance addiction treatment safety and efficacy. 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Why Intel Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
Via Benzinga
SciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy
From SciSparc Ltd
Via GlobeNewswire
SciSparc Advances $1.85 million Loan to AutoMax, Following AutoMax’s Direct Import Agreement with Major Chinese Vehicle Manufacturer
From SciSparc Ltd
Via GlobeNewswire
SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment
From SciSparc Ltd
Via GlobeNewswire
Clearmind Medicine Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment
From Clearmind Medicine Inc.
Via GlobeNewswire
SciSparc-Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based Combination
From SciSparc Ltd
Via GlobeNewswire
Why Affirm Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Via Benzinga
SciSparc Grants Global Rights for Pain Therapy to Biotech Company in Agreement Worth up to $6 Million
From SciSparc Ltd
Via GlobeNewswire
Why MIRA Pharmaceuticals Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket
Via Benzinga
SciSparc Submitted IND Application to the FDA for SCI-110 Phase IIb Clinical Trial for Patients with Tourette Syndrome
From SciSparc Ltd
Via GlobeNewswire
SciSparc: MitoCareX Appointed Professor Nir Peled, Seasoned Oncologist, to its Scientific Advisory Board
From SciSparc Ltd
Via GlobeNewswire
Autism CBD Trial On Children Advances As Israeli Company Enrolls First Five Patients
SciSparc Ltd. (NASDAQ: SPRC) announced on Tuesday that the first five patients have been enrolled and dosed into its ongoing clinical trial in children suffering from autism spectrum disorder (ASD) at... 
Via Benzinga
SciSparc Announces Enrollment of the First Five Patients in the Clinical Trial of its Innovative SCI-210 Treatment
From SciSparc Ltd
Via GlobeNewswire
Israeli Penny Stock Biotech SciSparc Outlicenses Its Cannabinoid Pain Therapy
SciSparc signs an exclusive license agreement with Polyrizon Ltd for its SCI-160 pain treatment program, with potential milestones of $3M in cash plus royalties. 
Via Benzinga
Why Xperi Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Via Benzinga
SciSparc Finalizes Exclusive Global Out-Licensing Agreement for its Pain Therapy Valued at $3 million
From SciSparc Ltd
Via GlobeNewswire
Nasdaq Jumps Over 2%; Walmart Earnings Top Views
Via Benzinga
Dow Surges Over 500 Points; US Retail Sales Rise In July
Via Benzinga
Topics Stocks
Exposures US Equities
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Pre-market stock movers are worth checking out on Thursday morning as we dive into all of the hottest news today! 
Via InvestorPlace
Why Lumentum Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket
Via Benzinga
SciSparc Updates Regarding the Status of the AutoMax Merger
From SciSparc Ltd
Via GlobeNewswire
SciSparc’s Collaboration with Clearmind Medicine Continues to Bear Fruit With New Scientific Article Showing MEAI Potential as a Novel Weight Loss Drug
From SciSparc Ltd
Via GlobeNewswire
SciSparc: MitoCareX Confirms Potential Significant Role of its Drug Target in Non-Small Cell Lung Cancer
From SciSparc Ltd
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.